Poll suggests oncologists already using GSK melanoma drugs off-label

Share this article:

A survey conducted by BioTrends Research Group found that of the U.S. oncologists polled, that  25% had prescribed GSK's BRAF-inhibitor Tafinlar for malignant melanoma, compared to 15% who said they prescribed GSK's MEK inhibitor, Mekinist. This study, part of the “LaunchTrends Tafinlar/Mekinist” report series, suggests the inability to differentiate between Taflinar and Mekinist is the most significant constraint for oncologists prescribing these new launch drugs. The report also alleges that oncologists may be using the two together in a non-FDA approved combination therapy. Another finding was that nearly half of oncologists surveyed are willing to prescribe both Taflinar and Mekinist as monotherapies. More oncologists also cited Tafinlar as the first-line BRAF-mutated unresectable/metastatic malignant melanoma treatment to be prescribed, Mekinist was cited as the most likely to prescribe in patients with the BRAF V600k Mutation.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs


Reimagining healthcare? We want to hear about it.
 
Submit nominations here for MM&M's first-ever list of the Top 40 Healthcare Transformers

Email Newsletters

MM&M inVISION

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.